Hillhouse Capital and RA Capital Lead Series D in Cytek Biosciences
Posted on 11/08/2020
Days ago, Fremont, California-based Cytek Biosciences Inc., a provider of cell analysis instrumentation and solutions, closed a US$ 120 million Series D funding round, co-led by RA Capital and Hillhouse Capital, with OrbiMed and LYFE Capital also participating. The investment will be used to expand Cytek’s global infrastructure, sustain its growing momentum and enable the company to deliver on its technology platform. Additionally, RA Capital and Hillhouse Capital have joined Cytek’s board of directors.
The company is headed by Dr. Wenbin Jiang who is an inventor of more than 90 U.S. patents.
Cytek’s cell analysis systems contain unique architectures that detect the full spectrum of the many fluorescent particles labeled on each cell. Cytek Biosciences Inc. is the outcome of a merger between Cytek Development Inc., a company engaged in flow cytometry, and Cytoville Inc., a venture capital backed business focused on advanced medical instrument technology development.
